This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentMaterialsVideosLet's connectLet's ConnectPfizer medical information
DosingDosingDosing ScheduleDose ModificationsAboutAboutStudy MethodologyEfficacy & SafetyEfficacy & Safety Progression-free Survival & Objective Response RateCNS EfficacyGuidelinesSafety TablesSafety Overview

Menu

Close

DosingDosingDosing ScheduleDose ModificationsTherapy ManagementTherapy ManagementHyperlipidaemiaOedemaILD/PneumonitisCNS EffectsSummarySupport & ServicesSupport & ServicesSummary of Prescribing InformationDownloadable ResourcesEvents & WebinarsVideosUseful Links

LORBRIQUA® (lorlatinib) is indicated for the treatment of adult patients with ALK+ metastatic NSCLC.1

Summary

  • Lorlatinib resulted in a significantly longer PFS, significantly higher overall and IC response rates, and improved global QoL compared to crizotinib in first-line, treatment-naïve ALK+ NSCLC 1-2
     
    • Lorlatinib IC response rate was 82% in patients with measurable brain metastases, with a complete response rate of 71% and significantly longer time to IC progression
        
    • HR of 0.02 (95% CI 0.002- 0.14) for time to IC progression in patients without brain metastases suggests a CNS protective effect
       
  • The safety profile of lorlatinib was similar to that reported in previous studies.1-4
     
    • Grade 3/4 AEs were more frequent with lorlatinib than crizotinib, however the majority were laboratory abnormalities that were asymptomatic and readily managed
        
  • These results support the use of lorlatinib as an effective first-line therapy for patients with advanced ALK+ NSCLC 1-3

    

AEs, adverse events; ALK, anaplastic lymphoma kinase; ALK+, anaplastic lymphoma kinase-positive; CNS, central nervous system; HR, hazard ratio; IC, intracranial; NSCLC, non-small cell lung cancer; PFS, progression-free survival; QoL, quality of life.​​​​​

    

Reference:

Shaw AT, Solomon BJ, Chiari R, et al. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2019 Dec;20(12):1691-1701.Solomon BJ, BauerT, Mok T, et al. Updated Efficacy and Safety From the Phase 3 CROWN Study of First-Line Lorlatinib vs Crizotinib in Advanced Anaplastic Lymphoma Kinase (ALK)–Positive Non-Small Cell Lung Cancer (NSCLC). Poster CT223 presented at the AACR Annual Meeting 2022, April 8-13, 2022; New Orleans, Louisiana, USA.Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018 Dec;19(12):1654-1667.Bauer TM, Felip E, Solomon BJ, Thurm H, Peltz G, et al. Clinical Management of Adverse Events Associated with Lorlatinib. Oncologist. 2019 Aug;24(8):1103-1110.

    

Please click the Prescribing Information link to view the safety and adverse events information of LORBRIQUA®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.​​​​​​

    

PP-LOR-IND-0129 June 2022

    

    

Summary


American Cancer Society

The American Cancer Society funds and conducts research, shares expert information and provides support for patients who have been affected by cancer.

Learn moreLoading


Lung Cancer Foundation of America

The Lung Cancer Foundation of America aims to improve the survivorship of patients with lung cancer through the funding of transformative science.

Learn moreLoading
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-LOR-IND-0129

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

 
Copyright © 2022 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • ​​​​​​​While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
 
For the use of Registered Medical Practitioners only*

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.


If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered Medical Practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
​​​​​​​Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-UNP-IND-0012 July 2022
Yes No
You are now leaving PfizerPro website
​​​​​​​ ​
​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?

PP-UNP-IND-0012 July 2022


​​​​​​​